(NASDAQ: ACRS) Aclaris Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 18.64%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.4%.
Aclaris Therapeutics's earnings in 2026 is -$75,738,000.On average, 14 Wall Street analysts forecast ACRS's earnings for 2026 to be -$97,077,670, with the lowest ACRS earnings forecast at -$106,748,637, and the highest ACRS earnings forecast at -$89,644,126. On average, 13 Wall Street analysts forecast ACRS's earnings for 2027 to be -$113,976,103, with the lowest ACRS earnings forecast at -$220,710,020, and the highest ACRS earnings forecast at -$66,460,300.
In 2028, ACRS is forecast to generate -$131,566,371 in earnings, with the lowest earnings forecast at -$220,710,020 and the highest earnings forecast at -$54,095,593.